Biogen Inc (BIIB)
159.99
-4.90
(-2.97%)
USD |
NASDAQ |
Nov 15, 16:00
160.99
+1.00
(+0.63%)
After-Hours: 20:00
Biogen Research and Development Expense (TTM): 2.080B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.080B |
| June 30, 2024 | 2.274B |
| March 31, 2024 | 2.344B |
| December 31, 2023 | 2.462B |
| September 30, 2023 | 2.493B |
| June 30, 2023 | 2.306B |
| March 31, 2023 | 2.25B |
| December 31, 2022 | 2.231B |
| September 30, 2022 | 2.329B |
| June 30, 2022 | 2.482B |
| March 31, 2022 | 2.539B |
| December 31, 2021 | 2.501B |
| September 30, 2021 | 3.528B |
| June 30, 2021 | 3.966B |
| March 31, 2021 | 4.029B |
| December 31, 2020 | 3.991B |
| September 30, 2020 | 2.956B |
| June 30, 2020 | 2.356B |
| March 31, 2020 | 2.193B |
| December 31, 2019 | 2.281B |
| September 30, 2019 | 2.200B |
| June 30, 2019 | 2.168B |
| March 31, 2019 | 2.664B |
| December 31, 2018 | 2.597B |
| September 30, 2018 | 2.573B |
| Date | Value |
|---|---|
| June 30, 2018 | 2.512B |
| March 31, 2018 | 2.327B |
| December 31, 2017 | 2.254B |
| September 30, 2017 | 2.200B |
| June 30, 2017 | 2.282B |
| March 31, 2017 | 1.959B |
| December 31, 2016 | 1.973B |
| September 30, 2016 | 1.981B |
| June 30, 2016 | 1.972B |
| March 31, 2016 | 1.990B |
| December 31, 2015 | 2.013B |
| September 30, 2015 | 1.971B |
| June 30, 2015 | 1.868B |
| March 31, 2015 | 1.825B |
| December 31, 2014 | 1.893B |
| September 30, 2014 | 1.816B |
| June 30, 2014 | 1.808B |
| March 31, 2014 | 1.689B |
| December 31, 2013 | 1.444B |
| September 30, 2013 | 1.367B |
| June 30, 2013 | 1.261B |
| March 31, 2013 | 1.263B |
| December 31, 2012 | 1.335B |
| September 30, 2012 | 1.329B |
| June 30, 2012 | 1.326B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.080B
Minimum
Sep 2024
4.029B
Maximum
Mar 2021
2.680B
Average
2.409B
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| Sage Therapeutics Inc | 253.20M |
| Pfizer Inc | 10.60B |
| Amgen Inc | 5.774B |
| Ionis Pharmaceuticals Inc | 912.60M |